Status:
COMPLETED
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Painful Diabetic Neuropathy and Post Herpetic Neuralgia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the efficacy and safety of pregabalin for the treatment of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN)
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of DPN or PHN
- Score on the Numeric Rating Scale of at least 4/10
- Exclusion Criteria:
- Hospitalized patients
- Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the assessment of DPN- or PHN-related pain
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT00629681
Start Date
November 1 2004
End Date
February 1 2006
Last Update
January 25 2021
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aachen, Germany, 52064
2
Pfizer Investigational Site
Albstadt, Germany, 72458
3
Pfizer Investigational Site
Berlin, Germany, 10117
4
Pfizer Investigational Site
Berlin, Germany, 10435